Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

Core Viewpoint - Cognition Therapeutics, Inc. has successfully closed a registered direct offering of 14,700,000 shares of common stock at a price of $2.05 per share, raising approximately $30 million in gross proceeds to advance its drug zervimesine for neurodegenerative disorders [1][2]. Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [6]. - The company has completed Phase 2 studies for its lead candidate, zervimesine (CT1812), targeting dementia with Lewy bodies, mild-to-moderate Alzheimer's disease, and geographic atrophy secondary to dry AMD [6]. Product Information - Zervimesine (CT1812) is an investigational oral medication designed for the treatment of CNS diseases, specifically Alzheimer's disease and dementia with Lewy bodies [4]. - The drug aims to interrupt the toxic effects of Aβ and ɑ-synuclein proteins, which are associated with neurodegeneration, potentially slowing disease progression and improving patient quality of life [4]. Financial Details - The offering was facilitated by Titan Partners Group, which acted as the sole placement agent [2]. - The shares were offered under a shelf registration statement previously filed with the U.S. Securities and Exchange Commission, which was declared effective on January 3, 2023 [2].